Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure)
Study Details
Study Description
Brief Summary
Small-molecule tyrosine kinase inhibitors（TKI) that target HER2 are routinely used to treat patients with HER2 (+) breast cancer. The main adverse reactions included diarrhea, nausea and rash, among which diarrhea had the highest incidence. It can reduce the quality of life and medication compliance of patients, and further affect the efficacy of TKI anti-tumor therapy. Therefore, we conducted this study to establish a risk assessment model before TKI treatment, in order to screen out the high-risk population and influencing factors of TKI-associated diarrhea, and planned to carry out corresponding animal experiments to verify the relationship between various mechanisms and the main mechanism in TKI-associated diarrhea, and to explore the corresponding treatment methods.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Diarrhea group Patients with diarrhea after taking pyrrolidine/naratinib，implement intervention (Yihuo 0.2g po bid+ Gold bifidum 2g po tid) |
Drug: Take probiotics
Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
|
| No Intervention: No diarrhea group Patients without diarrhea after taking pyrrolidine/naratinib |
Outcome Measures
Primary Outcome Measures
- Diarrhea grading [28 days]
Score according to the diarrhea grading：grading score： 0（None）；1（Increased bowel movements < 4 times per day compared to before treatment）； 2（Increased bowel movements 4 to 6 times/day or night compared to before treatment）；3（ Increased number of stools ≥ 7 times/day compared with before treatment, fecal incontinence, severe abdominal pain or fecal incontinence, affecting daily activities and requiring hospitalization）； 4（life-threatening (e.g. circulatory failure））；5（Death）.
Secondary Outcome Measures
- Time of the first occurrence of diarrhea [28 days]
The median time of the first occurrence of diarrhea
- Duration of diarrhea [28 days]
The median duration of diarrhea
- Time of the first occurrence of grade 3 diarrhea [28 days]
The median time of the first occurrence of grade 3 diarrhea
- Duration of grade 3 diarrhea [28 days]
The median duration of grade 3 diarrhea
- Adverse events [28 days]
Occurrence of other adverse events
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Plan to take pyrrolidine or naratinib for ≥ 28 days;
-
HER2 positive female patients with breast cancer aged ≥ 18 years and ≤ 65 years;
-
Patients with the following treatment schemes: 1. Pirotinib/naratinib monotherapy 2. Pirotinib/naratinib combined endocrine therapy; 4. The ECOG score is 0-1;
-
Life expectancy ≥ 6 months;
-
Patients who followed diet intervention after enrollment;
-
Volunteer to join the study, sign the informed consent form, have good compliance and are willing to cooperate with follow-up.
Exclusion Criteria:
-
People who may be allergic to pyrrolidine, naratinib or excipients;
-
There are many factors that affect the absorption of oral drugs, such as inability to swallow, nausea and vomiting;
-
Patients with biliary obstruction;
-
Participate in other clinical trials related to diarrhea;
-
Pregnant and lactating women, women with fertility and positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective contraceptive measures during the whole trial period;
-
According to the judgment of the investigator, there are concomitant diseases (including but not limited to severe hypertension and severe diabetes beyond drug control) that seriously endanger the patient's safety or affect the patient's completion of the study;
-
Have taken other drugs that may cause diarrhea adverse reactions within 3 weeks before enrollment;
-
There are drugs with high probability of causing diarrhea adverse reactions in patients' combined medication;
-
Any other situation in which the researcher believes that the patient is not suitable to participate in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong | China | 510000 |
Sponsors and Collaborators
- Sun Yat-sen University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SYSU-2022-01